Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Shabnam Jeibouei, Mohammad Esmael Akbari, Alireza Kalbasi, Amir Reza Aref, Mohammad Ajoudanian, Alireza Rezvani & Hakimeh Zali. (2019) Personalized medicine in breast cancer: pharmacogenomics approaches. Pharmacogenomics and Personalized Medicine 12, pages 59-73.
Read now
Read now
Li Zhou, Yifeng Ren, Xia Wang, Dongliu Miao, Analyn Lizaso, Haiyan Li, Han Han-Zhang, Jun Qian & Hui Yang. (2019) Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient– a case report. OncoTargets and Therapy 12, pages 5305-5309.
Read now
Read now
Andrea Rocca, Daniele Andreis, Anna Fedeli, Roberta Maltoni, Samanta Sarti, Lorenzo Cecconetto, Elisabetta Pietri, Alessio Schirone, Sara Bravaccini, Patrizia Serra, Alberto Farolfi & Dino Amadori. (2015) Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy. Expert Opinion on Drug Metabolism & Toxicology 11:10, pages 1647-1663.
Read now
Read now
Articles from other publishers (29)
Jingjing Xiong, Chaojun Yan, Qing Zhang & Jing Zhang. (2023) α-Ketoglutarate-dependent Enzymes in Breast Cancer and Therapeutic Implications. Endocrinology 164:6.
Crossref
Crossref
David C. Boyd, Emily K. Zboril, Amy L. Olex, Tess J. Leftwich, Nicole S. Hairr, Holly A. Byers, Aaron D. Valentine, Julia E. Altman, Mohammad A. Alzubi, Jacqueline M. Grible, Scott A. Turner, Andrea Ferreira-Gonzalez, Mikhail G. Dozmorov & J. Chuck Harrell. (2023) Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. Cancers 15:5, pages 1582.
Crossref
Crossref
Zihong Wu, Jiamei Wang, Fengming You, Xueke Li & Chong Xiao. (2023) The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer. Frontiers in Pharmacology 14.
Crossref
Crossref
Won-Min Song, Pei-Ling Chia, Xianxiao Zhou, Martin Walsh, Jose Silva & Bin Zhang. (2023) Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. iScience 26:2, pages 106064.
Crossref
Crossref
Abdelmoula El Abbouchi, Nabil El Brahmi, Marie-Aude Hiebel, Hamza Ghammaz, Elmostafa El Fahime, Jérôme Bignon, Gérald Guillaumet, Franck Suzenet & Saïd El Kazzouli. (2023) Improvement of the Chemical Reactivity of Michael Acceptor of Ethacrynic Acid Correlates with Antiproliferative Activities. Molecules 28:2, pages 910.
Crossref
Crossref
Desh Deepak Singh, Hae-Jeung Lee & Dharmendra Kumar Yadav. (2022) Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. Frontiers in Pharmacology 13.
Crossref
Crossref
Prasad Sanjay Dhiwar, Gurubasavaraja Swamy Purwarga Matada, Nulgumnalli Manjunathaiah Raghavendra, Abhishek Ghara, Ekta Singh, Nahid Abbas, Ganesh Sakaram Andhale, Ganesh Prasad Shenoy & Pujan Sasmal. (2022) Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer. Medicinal Chemistry Research 31:9, pages 1401-1413.
Crossref
Crossref
Victor-Bogdan Popescu, Krishna Kanhaiya, Dumitru Iulian Năstac, Eugen Czeizler & Ion Petre. (2022) Network controllability solutions for computational drug repurposing using genetic algorithms. Scientific Reports 12:1.
Crossref
Crossref
Érica C. M. Nascimento, Letícia de A. Nascimento, Luiz F. M. A. Benicio, José L. L. Alcântara, Washington A. de Pereira & João B. L. Martins. 2022. Research Topics in Bioactivity, Environment and Energy. Research Topics in Bioactivity, Environment and Energy
389
404
.
Yu-Li Lo, Hua-Ching Lin, Shu-Ting Hong, Chih-Hsien Chang, Chen-Shen Wang & Anya Maan-Yuh Lin. (2021) Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood–brain barrier model. Cancer Nanotechnology 12:1.
Crossref
Crossref
Kelvyn M. L. Rocha, Érica C. M. Nascimento & João B. L. Martins. (2021) Investigation on the interaction behavior of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein. Journal of Molecular Modeling 27:10.
Crossref
Crossref
Arthur Foulon, Pierrick Theret, Lise Rodat-Despoix & Philippe Kischel. (2020) Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. Cancers 12:9, pages 2634.
Crossref
Crossref
Juan Martín Cadena García, Carlos Eduardo Giraldo Murillo & Manuela Ramos Jaramillo. (2020) EGFR and HER2 small molecules inhibitors as potential therapeutics in veterinary oncology. Revista Colombiana de Ciencias Químico-Farmacéuticas 49:2.
Crossref
Crossref
Alexandra Canonici, Alacoque L. Browne, Mohamed F. K. Ibrahim, Kevin P. Fanning, Sandra Roche, Neil T. Conlon, Fiona O’Neill, Justine Meiller, Mattia Cremona, Clare Morgan, Bryan T. Hennessy, Alex J. Eustace, Flavio Solca, Norma O’Donovan & John Crown. (2020) Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer. Therapeutic Advances in Medical Oncology 12, pages 175883591989754.
Crossref
Crossref
Shu-Ting Hong, Huaching Lin, Chen-Shen Wang, Chih-Hsien Chang, Anya Maan-Yuh Lin, James Chih-Hsin Yang & Yu-Li Lo. (2019) Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. Journal of Nanobiotechnology 17:1.
Crossref
Crossref
Jieyi Di, Baotong Zheng, Qingfei Kong, Ying Jiang, Siyao Liu, Yang Yang, Xudong Han, Yuqi Sheng, Yunpeng Zhang, Liang Cheng & Junwei Han. (2019) Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities. Molecular Oncology 13:10, pages 2259-2277.
Crossref
Crossref
Jiani Wang & Binghe Xu. (2019) Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduction and Targeted Therapy 4:1.
Crossref
Crossref
Ramesh Butti, Sumit Das, Vinoth Prasanna Gunasekaran, Amit Singh Yadav, Dhiraj Kumar & Gopal C. Kundu. (2018) Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Molecular Cancer 17:1.
Crossref
Crossref
Cheng-Han Yu, Chi-Chi Chou, Hsin-Fang Tu, Wei-Chieh Huang, Ya-Yeh Ho, Kay-Hooi Khoo, Ming-Shyue Lee & Geen-Dong Chang. (2018) Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. Oncotarget 9:30, pages 21512-21529.
Crossref
Crossref
Fan Wang, Jeremy T-H. Chang, Zhenyu Zhang, Gladys Morrison, Aritro Nath, Steven Bhutra & Rong Stephanie Huang. (2017) Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile. Oncotarget 8:70, pages 115102-115113.
Crossref
Crossref
Xin Li, Changyong Yang, Hong Wan, Ge Zhang, Jun Feng, Lei Zhang, Xiaoyan Chen, Dafang Zhong, Liguang Lou, Weikang Tao & Lianshan Zhang. (2017) Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. European Journal of Pharmaceutical Sciences 110, pages 51-61.
Crossref
Crossref
Denis M. Collins, Kathy Gately, Clare Hughes, Connla Edwards, Anthony Davies, Stephen F. Madden, Kenneth J. O'Byrne, Norma O'Donovan & John Crown. (2017) Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. Cellular Immunology 319, pages 35-42.
Crossref
Crossref
Parthasarathy Seshacharyulu, Michael J Baine, Joshua J Souchek, Melanie Menning, Sukhwinder Kaur, Ying Yan, Michel M. Ouellette, Maneesh Jain, Chi Lin & Surinder K. Batra. (2017) Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1868:1, pages 69-92.
Crossref
Crossref
Yunting Zhu, Liang Li, Ge Zhang, Hong Wan, Changyong Yang, Xingxing Diao, Xiaoyan Chen, Lianshan Zhang & Dafang Zhong. (2016) Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Journal of Chromatography B 1033-1034, pages 117-127.
Crossref
Crossref
Monia Hossam, Deena S. Lasheen & Khaled A. M. Abouzid. (2016) Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles. Archiv der Pharmazie 349:8, pages 573-593.
Crossref
Crossref
Nadia Harbeck, Chiun-Sheng Huang, Sara Hurvitz, Dah-Cherng Yeh, Zhimin Shao, Seock-Ah Im, Kyung Hae Jung, Kunwei Shen, Jungsil Ro, Jacek Jassem, Qingyuan Zhang, Young-Hyuck Im, Marek Wojtukiewicz, Qiang Sun, Shin-Cheh Chen, Rainer-Georg Goeldner, Martina Uttenreuther-Fischer, Binghe Xu & Martine Piccart-Gebhart. (2016) Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. The Lancet Oncology 17:3, pages 357-366.
Crossref
Crossref
Wei-Chiao Huang, Pierre-Alain Burnouf, Yu-Cheng Su, Bing-Mae Chen, Kuo-Hsiang Chuang, Chia-Wei Lee, Pei-Kuen Wei, Tian-Lu Cheng & Steve R. Roffler. (2016) Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. ACS Nano 10:1, pages 648-662.
Crossref
Crossref
Burcu Cakar & Erdem Göker. 2016. Breast Disease. Breast Disease
617
631
.
Sheng-qi Wang, Shi-ting Liu, Bo-xin Zhao, Fu-heng Yang, Ya-tian Wang, Qian-ying Liang, Ya-bin Sun, Yuan Liu, Zhi-hua Song, Yun Cai & Guo-feng Li. (2015) Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1. Oncotarget 6:28, pages 26142-26160.
Crossref
Crossref